The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 21, 2020

Filed:

Mar. 19, 2019
Applicant:

Deutsches Krebsforschungszentrum Stiftung Des Ă–ffentlichen Rechts, Heidelberg, DE;

Inventors:

Christof Niehrs, Mainz, DE;

Olga Kazanskaya, Buchen, DE;

Bisei Okawara, Yokkaichi, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C07K 14/475 (2006.01); C12Q 1/6883 (2018.01); C07K 16/18 (2006.01); A61K 38/17 (2006.01); C12N 15/113 (2010.01); G01N 33/74 (2006.01); C07K 14/515 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
C07K 14/475 (2013.01); A61K 38/1703 (2013.01); A61K 39/3955 (2013.01); C07K 14/515 (2013.01); C07K 16/18 (2013.01); C12N 15/1136 (2013.01); C12Q 1/6883 (2013.01); G01N 33/74 (2013.01); C07K 2317/76 (2013.01); C12N 2310/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3233 (2013.01); C12Q 2600/106 (2013.01); G01N 2800/52 (2013.01); Y10T 436/143333 (2015.01);
Abstract

The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 arc angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.


Find Patent Forward Citations

Loading…